BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
HERZUMA (trastuzumab) by Celltrion is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERZUMA is a biosimilar trastuzumab (monoclonal antibody) that targets HER2/neu receptors on cancer cells. It is approved for treatment of HER2-positive breast cancer, gastric cancer, gastroesophageal junction cancer, and multiple other solid tumors. The drug works by binding to HER2 receptors, inhibiting tumor cell growth and promoting cell death.
$0.107BPart D
PeakHERZUMA is at peak lifecycle with modest Part D spending ($107K), indicating it captures a small share of the HER2-targeted oncology market; teams are likely focused on niche market defense and patient access rather than aggressive growth.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Started May 2026
60 enrolled
HER2-positive Recurrent or Metastatic Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Started Apr 2026
650 enrolled
HER2-positive Breast Cancer
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Started Apr 2026
596 enrolled
HER2-positive Breast Cancer
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Started Feb 2026
14 enrolled
Non-Small Cell Lung CancerNon-small Cell Lung Cancer Stage IINon-Small Cell Lung Cancer Stage IIIA+1 more
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Started Feb 2026
87 enrolled
HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Worked on HERZUMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.